Pancreatic cancer is the fourth most common cause of cancer-related mortality in Europe.1 Despite increased awareness, most patients continue to present with advanced disease. There has been minimal improvement in survival rates over the past 30 years, with overall 5-year survival remaining less than 8%.2 While these disappointing results are due to a multitude of host and treatment variables, it is apparent that, for a significant number of patients, poor nutritional and performance status are limiting factors to treatment choice, delivery, and tolerance.
Griffin O, Conlon KC. Sarcopenia—A New Frontier in the Management Care of Patients With Borderline Resectable Pancreatic Cancer. JAMA Surg. 2018;153(9):816. doi:10.1001/jamasurg.2018.1006
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.